Your browser doesn't support javascript.
loading
Comparison Between Heart Failure Without Left Ventricular Systolic Dysfunction and Progression to End-Stage in Hypertrophic Cardiomyopathy.
Nakagawa, Shoko; Okada, Atsushi; Irie, Yuki; Moriuchi, Kenji; Amano, Masashi; Amaki, Makoto; Kanzaki, Hideaki; Kusano, Kengo; Noguchi, Teruo; Kitai, Takeshi; Izumi, Chisato.
Afiliação
  • Nakagawa S; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Okada A; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Irie Y; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Moriuchi K; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Amano M; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Amaki M; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Kanzaki H; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Kusano K; Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.
  • Noguchi T; Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.
  • Kitai T; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
  • Izumi C; Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center.
Circ J ; 2024 Jun 21.
Article em En | MEDLINE | ID: mdl-38910134
ABSTRACT

BACKGROUND:

The incidence and prognostic predictors of heart failure (HF) without left ventricular systolic dysfunction (LVSD) in hypertrophic cardiomyopathy (HCM), particularly their differences in terms of developing LVSD (progression to end-stage) or sudden cardiac death (SCD), are not fully elucidated.Methods and 

Results:

This study included 330 consecutive HCM patients with left ventricular ejection fraction (LVEF) ≥50%. HF hospitalization without LVSD and development of LVSD were evaluated as main outcomes. During a median follow-up of 7.3 years, the incidence of HF hospitalization without LVSD was 18.8%, which was higher than the incidence of developing LVSD (10.9%) or SCD (8.8%). Among patients who developed LVSD, only 19.4% experienced HF hospitalization without LVSD before developing LVSD. Multivariable analysis showed that predictors for HF hospitalization without LVSD (higher age, atrial fibrillation, history of HF hospitalization, and higher B-type natriuretic peptide concentrations) were different from those of developing LVSD (male sex, lower LVEF, lower left ventricular outflow tract gradient, and higher tricuspid regurgitation pressure gradient). Known risk factors for SCD did not predict either HF without LVSD or developing LVSD.

CONCLUSIONS:

In HCM with LVEF ≥50%, HF hospitalization without LVSD was more frequently observed than development of LVSD or SCD during mid-term follow-up. The overlap between HF without LVSD and developing LVSD was small (19.4%), and these 2 HF events had different predictors.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Circ J Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Circ J Ano de publicação: 2024 Tipo de documento: Article